Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JBPOS0501
- Development stage
- Unknown
- Lead developer
- Bio-Pharm Solutions
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JBPOS0501 is an investigational small molecule developed by Bio-Pharm Solutions, currently in Phase 1 clinical development. It is being evaluated for a range of indications, including epilepsy, chronic pain, postpartum depression, and obesity. As a follow-on candidate to the company's lead asset JBPOS0101, JBPOS0501 is part of a pipeline focused on central nervous system (CNS) and rare diseases. The drug aims to leverage the company's expertise in small molecule chemistry to address unmet needs in neurological and metabolic health. While specific molecular targets for JBPOS0501 are not publicly detailed in early pipeline summaries, it is positioned as a key asset in the company's expanding portfolio.
Beyond the preview
Go deeper on JBPOS0501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JBPOS0501.